Usability Study of CEREBO® - A Novel Non-invasive Intracranial Bleed Detector
Sponsored by Bioscan Research Pvt. Ltd.
About this trial
Last updated 3 years ago
Study ID
BR/CV/2021/001
Status
Unknown status
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18+ Years
All
Trial Timing
Ended 2 years ago
What is this trial about?
Traumatic Brain Injury (TBI) is the leading cause of death and disability across the
globe. Time from injury to treatment is the most critical factor that determines the
patient's recovery. Mild TBI with no apparent symptoms are often left undiagnosed, thus
delaying the treatment and hence recovery. CEREBO® is a non-invasive, rapid,
near-infrared based, point-of-care device that can detect an intracranial bleed at an
early stage.
What are the participation requirements?
Inclusion Criteria
Operators - Medical health professionals >18 years of age with a valid medical license to practice medicine belonging to one of the following categories and have given a written consent to participate in the study. 1. MBBS with Specialisation 2. MBBS 3. Nursing Staff 4. Others Subjects - 1. Subjects with suspected traumatic brain injury and GCS > 13 2. Of all ages and gender, have understood the study and gave a written informed consent.
Exclusion Criteria
Subjects - 1. Subjects with active bleeding or scalp laceration 2. Subjects with large extracranial lesions